DelveInsight’s, “Encephalopathy Pipeline Insight 2023” report provides comprehensive insights about 70+ Encephalopathy companies and 70+ pipeline drugs in the Encephalopathy pipeline landscape. It covers the Encephalopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Encephalopathy Pipeline Report
- DelveInsight’s Encephalopathy pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Encephalopathy treatment.
- The leading companies working in the Encephalopathy market include Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Q-State Biosciences Inc., Ocera Therapeutics, and others.
- Promising Encephalopathy Pipeline Therapies in the various stages of development include RLS-0071, TAK-935, VSL#3, Rifaximin SSD, AST-120, Ornithine Phenylacetate, Flortaucipir F18, ZX008 (Fenfluramine Hydrochloride), Standard Medical Therapy, Lactulose, HPN-100, and others.
- On April 2023, Bausch Health Americas Inc. announced a study of Phase 3 Clinical Trials for Rifaximin SSD. Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.
- On August 2023, ReAlta Life Sciences Inc. announced a study of Phase 2 Clinical Trials for RLS-0071. This is a Phase 2, two-stage, multisite, randomized, double-blind, placebo-controlled, multiple-ascending dose study of RLS-0071 to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy in newborns with moderate or severe HIE undergoing therapeutic hypothermia.
Request a sample and discover the recent advances in Encephalopathy Treatment Drugs @ Encephalopathy Pipeline Report
The Encephalopathy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Encephalopathy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Encephalopathy clinical trial landscape.
Encephalopathy Overview
Encephalopathy is a broad term used to describe abnormal brain function or brain structure. (Encephalo= brain + pathy= disorder). The abnormality may be transient, recurrent, or permanent. The loss of brain function may be reversible, static and stable, or progressive with increasing loss of brain activity over time.
Find out more about Encephalopathy Treatment Landscape @ Drugs for Encephalopathy Treatment
Encephalopathy Emerging Drugs Profile
- XEN496: Xenon Pharmaceuticals
- AXA 1665: Axcella Health
- RBX 7455: Rebiotix
Encephalopathy Pipeline Therapeutics Assessment
The Encephalopathy pipeline report proffers an integral view of the Encephalopathy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Learn more about the emerging Encephalopathy Pipeline Therapies @ Encephalopathy Clinical Trials Assessment
Scope of the Encephalopathy Pipeline Report
- Coverage- Global
- Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Encephalopathy Companies- Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Q-State Biosciences Inc., Ocera Therapeutics, and others.
- Encephalopathy Pipeline Therapies- RLS-0071, TAK-935, VSL#3, Rifaximin SSD, AST-120, Ornithine Phenylacetate, Flortaucipir F18, ZX008 (Fenfluramine Hydrochloride), Standard Medical Therapy, Lactulose, HPN-100, and others.
Dive deep into rich insights for new drugs for Encephalopathy Treatment, Visit @ Encephalopathy Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Encephalopathy: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Encephalopathy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- XEN496: Xenon Pharmaceuticals
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- RBX 7455: Rebiotix
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug Name; Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Encephalopathy Key Companies
- Encephalopathy Key Products
- Encephalopathy – Unmet Needs
- Encephalopathy – Market Drivers and Barriers
- Encephalopathy – Future Perspectives and Conclusion
- Encephalopathy Analyst Views
- Encephalopathy Key Companies
- Appendix
For further information on the Encephalopathy Pipeline therapeutics, reach out to Encephalopathy Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market